Page 218 - 2020_01-Haematologica-web

M. Beksac et al.
22. Paubelle E, Coppo P, Garderet L, et al.
Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including haematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702-1704.
23. Rosiñol L, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myelo- ma. Eur J Haematol. 2006;76(5):405-408.
24. Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832-836.
25. Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of
response of soft-tissue plasmacytomas. Br J
Haematol. 2001;113(2):422-425.
26. Anagnostopoulos A, Gika D, Hamilos G, et al. Treatment of relapsed refractory multi- ple myeloma with thalidomide-based regi- mens: identification of prognostic factors.
Leuk Lymphoma. 2004;45(11):2275-2279. 27. Jiménez-Segura R, Granell M, Gironella M, et al. Pomalidomida/dexametasona en el tratamiento de la enfermedad extramedular en pacientes con myeloma multiple en recaída/refractario: análisis de 16 casos.
Haematologica. 2016;101(s4):103.
28. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over- represented in high-risk disease even in the era of novel agents. Hematologica.
2012;97(11):1761-1767.
29. Kumar L, Gogi R, Patel AK, et al. Multiple
myeloma with extramedullary disease: impact of autologous stem cell transplanta- tion on outcome. Bone Marrow Transplant. 2017;52(10):1473-1475.
30. Gagelmann N, Eikerna DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890-897.
31. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myelo- ma prognosis is significantly worse in com- parison to bone-related extramedullary relapse. Hematologica. 2014;99(2):360-364.
208
haematologica | 2020; 105(1)